Kim et al. demonstrated that re-expression (activation) of RUNX3 enhances the susceptibility of NSCLC to Sc-conjugated cetuximab, and that clinical efficacy can be improved through the combined use of therapeutics with RUNX3 activity [181]. Here, RUNX3 is linked to non-small cell lung carcinoma.